Our ADP-A2AFP SPEAR T-cell product targets alpha- fetoprotein (AFP) is being investigated in an ongoing Phase I clinical trial for the treatment of patients with hepatocellular carcinoma (liver cancer).
Overview
Pipeline
| SPEAR T-cell |
Target | Indications | Target dose (Cohort) | 5 BN+ (expansion) |
Registration studies |
||
|---|---|---|---|---|---|---|---|
| 100 M (1) | 1 BN (2) | 5 BN (3) | |||||
| ADP-A2AFP | AFP | Hepatocellular carcinoma |
100 M (1) Phase complete
|
1 BN (2) Phase in progress
|
5 BN (3) Phase not started
|
5 BN+ (expansion) Phase not started
|
Registration studies Phase not started
|